https://pharmadog.xyz/news/595723 pharmadog en 2026-10-26T10:34:34.000Z BioNTech, DualityBio weigh future of HER2 ADC after modest Phase 3 breast cancer results https://pharmadog.xyz/news/595431 pharmadog en 2026-10-26T09:00:00.000Z Experts unveil four-stage framework for women's heart health across the lifespan https://pharmadog.xyz/news/595451 pharmadog en 2026-10-26T09:00:00.000Z Overlooked drugs can gain value when markets evolve, says Azurity CEO https://pharmadog.xyz/news/595620 pharmadog en 2026-10-26T09:00:00.000Z Manufacturing hurdles grow as next-gen protein therapeutics gain traction https://pharmadog.xyz/news/595433 pharmadog en 2026-10-26T08:30:00.000Z NIH launches vaccine injury center that will also study long-term post-infection symptoms https://pharmadog.xyz/news/595434 pharmadog en 2026-10-26T08:30:00.000Z Patient feels exhausted despite normal labs, highlighting stress and lifestyle factors https://pharmadog.xyz/news/595432 pharmadog en 2026-10-26T08:30:00.000Z Moderna CEO Bancel optimistic after Phase 3 success of mRNA melanoma vaccine intismeran https://pharmadog.xyz/news/595435 pharmadog en 2026-10-26T08:30:00.000Z Researchers warn long-term AI use may foster social isolation, call for better data access https://pharmadog.xyz/news/595530 pharmadog en 2026-10-26T05:07:00.000Z Tango Therapeutics reports 82% response rate for PRMT5 inhibitor combo in pancreatic cancer trial https://pharmadog.xyz/news/594631 pharmadog en 2026-10-26T04:02:00.000Z Taysha and Neurogene close in on first Rett syndrome gene therapy as 2027 readouts loom https://pharmadog.xyz/news/594632 pharmadog en 2026-10-26T04:01:00.000Z Australian clinical trials attract more U.S. sponsors amid regulatory uncertainty https://pharmadog.xyz/news/593235 pharmadog en 2026-10-25T21:43:13.000Z Akeso reports survival benefit for ivonescimab in China-only biliary tract cancer trial, likening results to Keytruda https://pharmadog.xyz/news/592223 pharmadog en 2026-10-25T16:58:45.000Z AstraZeneca highlights broad oncology portfolio at ESMO conference https://pharmadog.xyz/news/592012 pharmadog en 2026-10-25T15:30:51.000Z Roche's KRAS G12C inhibitor cuts death risk by 44% versus Amgen and BMS in lung cancer trial https://pharmadog.xyz/news/592013 pharmadog en 2026-10-25T15:30:09.000Z AstraZeneca reports Tagrisso-Orpathys combo could prolong treatment for EGFR-mutant lung cancer https://pharmadog.xyz/news/594078 pharmadog en 2026-10-25T12:03:00.000Z ESMO: BMS’ Massacesi hails ‘very promising’ data for BioNTech-partnered PD-L1xVEGF-A drug https://pharmadog.xyz/news/591083 pharmadog en 2026-10-25T10:00:51.000Z Pfizer shifts focus after lung cancer trial setback, cites early signals in earlier-line patients; BioNTech and BMS report initial activity https://pharmadog.xyz/news/592156 pharmadog en 2026-10-25T09:47:00.000Z J&J touts promising RIPTAC data with 59% PSA reductions in prostate cancer trial https://pharmadog.xyz/news/590683 pharmadog en 2026-10-25T08:31:01.000Z Merck and Moderna’s mRNA melanoma vaccine cuts recurrence risk by 42% in Phase 3 trial https://pharmadog.xyz/news/588254 pharmadog en 2026-10-24T18:23:00.000Z Tonight We Ride recalls Ultimate Forza male supplement after finding undeclared sildenafil, tadalafil and dapoxetine https://pharmadog.xyz/news/587731 pharmadog en 2026-10-24T17:00:59.000Z Amgen and AstraZeneca present new combo data for extensive-stage small cell lung cancer at ESMO https://pharmadog.xyz/news/587411 pharmadog en 2026-10-24T16:00:12.000Z AstraZeneca, Lilly and Bayer unveil new strategies at ESMO 2026 in Madrid https://pharmadog.xyz/news/587075 pharmadog en 2026-10-24T14:30:56.000Z Amgen's Imdelltra plus AstraZeneca's Imfinzi cuts death risk by 58% in small cell lung cancer Phase 3 trial